Radisys Showcases Connect Open Broadband Portfolio at Broadband World Forum 2021
11.10.2021 09:00:00 EEST | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Connect Open Broadband solution showcase in Booth A24 at Broadband World Forum 2021, with the event exhibition taking place October 13-14 in Amsterdam, and the online event occurring October 11-15. Radisys will present live demonstrations that enable broadband service providers to transform their networks, simplify network operations, and be prepared to meet their customers’ changing needs. Radisys will demonstrate triple-play services, including high-speed internet and video streaming over Gigabit-PON (G-PON) and XGS-PON, and its Smart Home portfolio—including the Radisys Reach Smart Home Gateway and customizable mobile application—along with a sampling of available sensors, cameras and other devices that work together as an integrated solution.
Radisys will join other industry thought leaders in sessions exploring broadband innovation:
- Rajesh Chundury, VP of Customers Solutions, will present, “Advance Your FTTx Network with Cloud-Native Containerized Solutions for PON” on October 11 at 10:30am in the virtual session and live in-person October 14 from 2:10pm-2:30pm.
- Chundury will also participate in the Open Networking Foundation’s workshop “Taking opensource to production in broadband network with VOLTHA, a community view” on October 13, 3:00pm-5:00pm. The discussion will also feature experts from Adtran, Deutsche Telekom, Netsia and Türk Telekom.
The Radisys showcase will feature key solutions from its broadband and Smart Home portfolios. The demonstrations will include the Connect Broadband Access Controller (CBAC)-C (Centralized) and CBAC-D (Distributed) deployments using Radisys’ RLT-1600G and RLT-1600X Optical Line Terminals (OLTs) for fiber to the x (FTTX) deployments.
- Radisys’ CBAC software enables service providers to evolve their fiber networks with an open software solution that facilitates faster product innovation cycles, increased automation, and deeper network visibility.
- The Radisys Combo PON OLT features full PON port flexibility and enables broadband providers to leverage G-PON technology while also providing the option to expand their network and rollout XGS-PON deployments using the same OLT hardware at their pace and optimizing their cost model.
- Radisys’ Optical Network Terminals (ONTs) are built with inherent efficiencies and scalability to support data, voice, video and other broadband services for residential and commercial subscribers on fiber networks.
- Radisys’ Smart Home solutions help service providers broaden the utility of their data plans with life-enriching services and features that consumers want, to create new revenue streams and increase average revenue per user.
“Radisys is delivering best-in-class devices and leading software solutions that add value to the broadband ecosystem, elevating broadband service provider offerings and enhancing their data plans,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Broadband World Forum 2021 is an exciting opportunity to showcase our portfolio that enables service providers to expand their fiber networks with world class solutions and leverage an open device ecosystem to create new revenue streams.”
To see the technology demonstrations, or to meet with Radisys’ open telecom experts at Broadband World Forum 2021, contact open@radisys.com.
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005025/en/
Contact information
Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom